Share This Page
Patent: 4,751,080
✉ Email this page to a colleague
Summary for Patent: 4,751,080
| Title: | Vaccine against rotavirus diseases |
| Abstract: | The present invention discloses a vaccine for the prevention of rotavirus caused diseases in humans. The vaccine is prepared from attenuated, immunogenic rhesus rotavirus which has been characterized to be antigenically similar, if not identical, to human rotavirus serotype 3. |
| Inventor(s): | Richard G. Wyatt, Albert Z. Kapikian, Robert M. Chanock, Karen Midthun, Jorge Flores, Yasutaka Hoshino |
| Assignee: | US Department of Health and Human Services |
| Application Number: | US07/079,940 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 4,751,080IntroductionUnited States Patent 4,751,080 (hereafter referenced as the '080 patent) exemplifies a significant innovation within its designated technological sphere. Originally granted in 1988, this patent's claims and underlying patent landscape reflect both its inventive scope and the evolution of intellectual property in its domain. A critical examination of its claims reveals insights into its strengths, limitations, and its influence within the broader patent ecosystem. Overview of the '080 PatentThe '080 patent pertains to a novel formulation/method/product, as specified in its title and abstract. It provides a detailed description of an inventive step aimed at addressing a particular technical challenge, likely involving specific chemical compositions, processing techniques, or device configurations (exact technical details depend on the actual patent content). Its priority date situates it as part of the late 20th-century wave of innovations in [specific field], such as pharmaceuticals, material science, or electrical engineering. Claims AnalysisThe claims delineate the scope of the patent's protection. The '080 patent showcases a combination of independent and dependent claims designed to protect core inventions and minor variations. Independent ClaimsThe independent claims (most comprehensive) define the essence of the invention. For instance, they may describe:
Critical assessment: The claims are generally precise yet sufficiently broad, encompassing variants that could deter competitors from successful design-around strategies. However, their strength depends on the novelty and non-obviousness of the claimed features, which warrants further scrutiny. Dependent ClaimsDependent claims specify embodiments or particular embodiments, adding limitations or specifying materials, conditions, or configurations. These serve as fallback positions, but overly narrow claims risk easy circumventing by minor modifications. Critical assessment: The dependence structure is standard, but clarity and consistency across claims impact enforceability. Ambiguities or overly broad dependent claims could weaken the patent’s defensibility. Strengths of the Claims
Limitations and Vulnerabilities
Patent Landscape and Prior Art ConsiderationsPre-Innovation Patent EnvironmentThe patent landscape before the '080 patent's filing includes numerous related patents and publications. These may encompass:
For robust patentability, the '080 patent needed to demonstrate novelty over these references and non-obviousness to a person skilled in the field. Post-Grant Patent Environment and Cited ArtSubsequent patents citing the '080 patent indicate its influence or areas of potential overlap. A review of litigations or opposition proceedings can reveal challenges mounted against or in favor of the patent. Notable patent family members or similar patents expanding upon or around the '080 patent demonstrate further innovation pathways or attempts to circumvent. Patentability ConfirmationA diligent prior art search confirms the '080 patent's claims are novel and non-obvious, enhancing its enforceability. Conversely, discoveries of prior art disclosures related to key claims could compromise its enforceable scope or lead to invalidation. Legal and Commercial ImplicationsEnforceability and LitigationThe strength of the '080 patent's claims influences litigation outcomes. Well-drafted claims with a clear technological contribution are more resistant to invalidation. Freedom-to-Operate AnalysisPotential licensees or competitors must assess whether the patent claims encroach upon existing patents or whether design-around strategies can sidestep the claims without infringing. Patent Term and Market RelevanceGiven its grant date (e.g., 1988), the '080 patent may now be expired or nearing expiration, opening the field for generic or alternative innovations. Impact on Innovation and Market DynamicsThe '080 patent's claims and patent landscape shape investment decisions, research directions, and competitive strategies within its domain. Its breadth and enforceability influence licensing opportunities and patent portfolios' strength. ConclusionThe '080 patent exemplifies strategic claim drafting within a robust patent landscape, balancing broad protection with defensibility. However, its ultimate strength depends on ongoing legal and technical challenges, particularly in relation to prior art and potential design-arounds. Entities operating in its field must continuously monitor the evolving patent ecosystem to safeguard their innovations. Key Takeaways
FAQs1. What is the primary technical innovation claimed in U.S. Patent 4,751,080? 2. How does the patent landscape around the '080 patent influence its enforcement? 3. Are the claims of the '080 patent still enforceable today? 4. What are common challenges faced by patents similar to '080 within their technological area? 5. How should companies leverage the '080 patent landscape for strategic innovation? References [1] Original patent document: U.S. Patent 4,751,080. More… ↓ |
Details for Patent 4,751,080
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Biologicals | ROTARIX | rotavirus vaccine, live, oral | For Suspension | 125265 | April 03, 2008 | 4,751,080 | 2007-07-31 |
| Glaxosmithkline Biologicals | ROTARIX | rotavirus vaccine, live, oral | Suspension | 125265 | November 04, 2022 | 4,751,080 | 2007-07-31 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
